Overview
A nine-amino-acid neurohypophysial hormone produced in the hypothalamus and released from the posterior pituitary. It is one of the best-characterised peptides in this database, with an established clinical role in obstetrics and an extensive research literature in social and behavioural neuroscience.
Mechanism of Action
Oxytocin binds the oxytocin receptor, a G-protein-coupled receptor signalling largely through Gq and phospholipase C, raising intracellular calcium.
In peripheral tissue this drives uterine smooth muscle contraction and myoepithelial contraction in mammary tissue, the basis of its established clinical uses.
Centrally, oxytocinergic projections from the paraventricular nucleus reach the amygdala, nucleus accumbens and other limbic regions, where published work reports modulation of social salience and stress reactivity.
It shares structural similarity with vasopressin and shows measurable cross-reactivity at vasopressin receptors, which reviews cite as a confound in interpreting behavioural studies.
Areas Being Studied
- Obstetric use (established clinical indication)
- Social cognition and affiliative behaviour research
- Anxiety and stress-response research
- Veterinary obstetrics and lactation
Listing a research area does not imply efficacy, approval, or suitability for any use.
Research Summary
- Oxytocin is an approved medicine for labour induction and postpartum haemorrhage management, with a large clinical evidence base for those specific indications.
- Intranasal oxytocin has been studied extensively in social cognition, autism and anxiety research; results are mixed, and several well-powered trials have reported null findings.
- Reviews question how much intranasally administered peptide reaches central targets, a major open methodological issue in this field.
- Animal work provides the strongest mechanistic support for its role in pair bonding and maternal behaviour.
Potential Adverse Effects Reported in Research
- In clinical obstetric use, reported effects include uterine hyperstimulation, nausea, and, with high-volume administration, hyponatraemia due to antidiuretic activity.
- Cardiovascular effects including hypotension and tachycardia are documented at clinical intravenous doses.
- Intranasal research studies generally report mild effects such as nasal irritation and headache.
- Reviews note that oxytocin is a hormone with broad physiological activity and should not be treated as a benign supplement-like compound.
Reconstitution Basics
Research-grade material is supplied as a lyophilised powder; clinical formulations are supplied as sterile solutions. Laboratory documentation describes reconstitution with bacteriostatic water and cold storage of the resulting solution.
Bacteriostatic water
Sterile water containing roughly 0.9% benzyl alcohol as a preservative, which inhibits bacterial growth in multi-access vials.
Sterile technique
Laboratory documentation describes disinfecting the stopper, using a fresh sterile needle for each access, and avoiding contact with non-sterile surfaces.
After reconstitution
Solutions are refrigerated, protected from light, and not subjected to repeated freeze–thaw cycles.
This section is educational background on laboratory handling. It is not an instruction or protocol.
Open the reconstitution calculator →Dosing & Reconstitution Guide
Oxytocin has an established obstetric role with strict clinical protocols, and a separate research literature using single intranasal doses in social-cognition studies.
Protocol overview
- Intranasal research doses are single, task-linked administrations, not daily regimens.
- Obstetric intravenous use is a monitored hospital procedure and is not comparable to research intranasal dosing.
- The very short half-life (~1–6 minutes) means effects in studies are measured in a narrow window.
Dosing protocol — standard titration
| Phase | Reported dose | Notes |
|---|---|---|
| Research setting | Single intranasal dose (commonly 24 IU)Given ~45 minutes before a task. | Given ~45 minutes before a task. |
| Repeat sessions | Same single dose per sessionSessions separated by days in crossover designs. | Sessions separated by days in crossover designs. |
| Clinical setting | Titrated IV infusionHospital-only, continuously monitored. | Hospital-only, continuously monitored. |
Dosing protocol — gradual titration
| Phase | Reported dose | Notes |
|---|---|---|
| Session 1 | Lower intranasal amountSome protocols compare 12 IU and 24 IU. | Some protocols compare 12 IU and 24 IU. |
| Session 2+ | Standard research doseDose–response studies are limited. | Dose–response studies are limited. |
| Ongoing | Not establishedChronic intranasal schedules lack safety data. | Chronic intranasal schedules lack safety data. |
Schedules summarise what appears in published studies, trial protocols or manufacturer documentation. They are reference material, not a recommendation.
Where to Buy Compounds & Supplies
External link. PepDex does not sell products and does not endorse any supplier.
Supplies needed
Lyophilised peptide vial
Sealed vial with an intact stopper and a legible mass label (mg or mcg).
Bacteriostatic water
Sterile water with ~0.9% benzyl alcohol, used where a vial will be accessed more than once. Sterile water for injection is used for single-access work.
Reconstitution syringe
A 1–3 mL syringe with a larger-gauge needle for drawing and transferring solvent.
Insulin syringe (U-100)
Fine-gauge syringe graduated in units; 100 units = 1 mL. Used for accurate small-volume measurement.
Alcohol prep pads
70% isopropyl swabs for disinfecting both vial stoppers before every access.
Sharps container
Rigid, puncture-resistant container for single-use needle disposal.
Refrigeration and light protection
2–8 °C storage plus an opaque box or the original carton for reconstituted vials.
Labels
Date of reconstitution, resulting concentration and compound name on every vial.
Reconstitution steps
- 01
Bring the vial to room temperature
Lyophilised powder is allowed to equilibrate out of the refrigerator before the stopper is pierced, which reduces condensation inside the vial.
- 02
Disinfect both stoppers
The peptide vial and the bacteriostatic water vial are each swabbed with 70% isopropyl alcohol and allowed to air dry.
- 03
Draw the calculated solvent volume
Solvent volume is chosen to produce a convenient concentration — the reconstitution calculator converts vial mass and solvent volume into concentration and syringe units.
- 04
Add the solvent slowly down the vial wall
The stream is directed against the glass rather than onto the powder cake. Peptides are shear-sensitive and direct jetting is avoided.
- 05
Dissolve without shaking
The vial is left to stand, then gently swirled or rolled. Shaking introduces foam and mechanical stress that can denature peptide chains.
- 06
Inspect the solution
Documentation describes checking for a clear, particle-free solution. Cloudiness, visible particulate or discolouration is treated as a failed preparation.
- 07
Label and refrigerate
The vial is labelled with compound, concentration and date, then stored at 2–8 °C protected from light.
Storage instructions
- Before reconstitution: refrigerated at 2–8 °C; commercial preparations state their own conditions.
- After reconstitution or opening: refrigerated and used within the period stated by the preparation, typically weeks.
- Protection from light: kept in the carton; oxytocin solutions are stored away from heat.
- Freezing is avoided for aqueous oxytocin preparations.
- Discard on any change in clarity.
Half-Life
~1–6 minutes
Plasma half-life is very short due to rapid degradation by oxytocinase and other peptidases; clinical infusion protocols exist specifically because of this rapid clearance.
Storage
- Before reconstitution
- Lyophilised powder stored frozen; clinical solutions per their labelled conditions.
- After reconstitution
- Refrigerated at 2–8 °C after reconstitution.
- Light protection
- Protected from light.
- Shelf-life considerations
- Reconstituted research solutions are typically described as usable for a few weeks refrigerated.
Frequently Asked Questions
References
Related peptides
DSIP
A nonapeptide first isolated from rabbit cerebral venous blood during induced slow-wave sleep. It is studied in sleep architecture, stress-response and endocrine regulation models, and its physiological role remains incompletely characterised.
Semax
A synthetic heptapeptide based on the ACTH(4-10) fragment with a Pro-Gly-Pro extension. It is studied primarily in neuroprotection, ischaemic stroke recovery and attention or memory endpoints, and carries no corticotropic hormonal activity.
Selank
A synthetic heptapeptide derived from the immune peptide tuftsin, developed in Russia and studied predominantly in anxiety, stress-response and cognitive models. It is most often described in the literature as an anxiolytic-type research peptide without sedative properties.
Educational reference only. Figures are compiled from published research literature. PepDex does not provide medical advice, dosing recommendations, or instructions for use.